NCBiotech News

Paris-based Cellectis has successfully dosed its first U.S. patient with its UCART22 allogeneic CAR T-cell therapy product candidate that it made in its new Raleigh facility.

Boone-based MOLTOX gets International Organization for Standardization ISO 9001:2015 certification.

There'll be job info galore at the free public Biomanufacturing and Process Development BioGrow Training and Education Symposium on Thursday, Feb. 9, from 12:30 to 5 p.m. at NCBiotech.

Target RWE, a Durham-based clinical analytics company, has launched 35 new observational disease-state registries to support decision-making in health care.

 

Chaseman Global, an international life sciences executive recruitment company, opened a regional office today at the North Carolina Biotechnology Center’s Landing Pad rental office site.

RTP-based AskBio has signed a multi-year research collaboration and option agreement with Bay-area firm ReCode Therapeutics to develop gene-editing technology for driving new precision therapies.

Datar Cancer Genetics, a global company developing blood-based diagnostics for cancer, with a U.S. base in Morrisville, has received the FDA’s breakthrough devices designation for its non-invasive test to help diagnose brain tumors.

Life sciences and related companies from around the world announced new or expanded facilities in 2022 that will bring more than $2.1 billion in investment and over 2,700 new jobs to North Carolina.

Mazen Animal Health, an Iowa startup company that’s developing corn-based oral vaccines for animals, has selected the Research Triangle Park as the home for its research and development center.

Polarean Imaging, a Durham medical imaging technology company, has received FDA clearance for a drug and device combination product that helps doctors visualize lung function in patients with chronic lung disease

RTP gene therapy startup Opus Genetics has acquired the rights to two pre-clinical product candidates to treat inherited retinal diseases from New Jersey biopharm company Iveric Bio.

Durham's Altis Biosystems is granting Plakous Therapeutics up to $10K to support development of the Winston-Salem company's drug to treat necrotizing enterocolitis.

Greensboro-based Kepley Biosystems has netted a $1M NSF grant to support its work growing horseshoe crabs and using their blue blood for diagnostic purposes.

A little bit of Sweden has migrated to North Carolina with the opening of TFS HealthScience’s U.S. headquarters in Durham.